Robert W. Baird initiated coverage on Dyne Therapeutics with a new price target

12/13/24 7:36:12 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Robert W. Baird initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $46.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DYN

Date	Price Target	Rating	Analyst
6/24/2025	$13.00	Mkt Perform	Bernstein
6/11/2025	$37.00	Outperform	Raymond James
6/2/2025	$34.00	Outperform	Oppenheimer
5/29/2025	$46.00	Outperform	Evercore ISI
3/12/2025	$50.00	Outperform	BMO Capital Markets
3/7/2025	$50.00	Sector Outperform	Scotiabank
12/13/2024	$46.00	Outperform	Robert W. Baird
11/26/2024	$45.00	Outperform	RBC Capital Mkts